Hot Investor Profile: Life Science-Focused VC Seeks Innovative Early and Mid-Stage Therapeutics Companies in Europe, Investing Up to €20M

29 Aug

A leading Europe-based venture capital firm provides private equity financing to early- and mid-stage, highly innovative life science companies bringing life-changing therapeutic treatments to patients, with a focus on indications with high unmet needs. The firm has a diverse international team that is driven by science, with the ambition to transform capital into medical breakthroughs. The firm was founded in 2008 and has over 400M€ million in assets under management through its three funds. The investments typically range from 5 million to 20 million, including additional capital for follow-on investments. 
 
The firm invests in innovative therapeutics. The firm focuses on indications with a clear unmet need, and prefers to invest in opportunities that have realistic exit potential in 2-3 years. In case of niche/orphan indications, the potential market share should be significant and realistic. The firm invests in small molecules, biologics and advanced therapies. At minimum, the product should have solid animal data. 
 
The firm looks for a cohesive management team with a proven track record, including relevant business experience and top-notch scientific know-how. The firm requires a board seat in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Leave a comment